Pfizer Inc. $PFE Shares Bought by U.S. Capital Wealth Advisors LLC

Key Points

• U.S. Capital Wealth Advisors LLC increased its stake in Pfizer Inc. by 15.5%, acquiring an additional 61,977 shares, bringing their total holdings to 461,949 shares valued at $11.2 million.
• Despite a slight decrease of 0.5% in share price, Pfizer reported a strong quarterly earnings performance, with an EPS of $0.78, surpassing expectations and showcasing a year-over-year revenue growth of 10.3%.
• Wall Street analysts have mixed opinions on Pfizer, with a consensus rating of "Hold" and a target price of $28.12, reflecting caution amidst varying price targets from different firms.

U.S. Capital Wealth Advisors LLC increased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 15.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 461,949 shares of the biopharmaceutical company's stock after purchasing an additional 61,977 shares during the period. U.S. Capital Wealth Advisors LLC's holdings in Pfizer were worth $11,198,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Capital Advisory Group Advisory Services LLC lifted its stake in Pfizer by 2.9% during the 2nd quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock valued at $328,000 after acquiring an additional 388 shares during the period. Trust Co of the South lifted its position in Pfizer by 1.5% during the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock valued at $712,000 after purchasing an additional 441 shares during the period. Charter Oak Capital Management LLC lifted its position in Pfizer by 4.3% during the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company's stock valued at $258,000 after purchasing an additional 444 shares during the period. Members Trust Co lifted its position in Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock valued at $587,000 after purchasing an additional 467 shares during the period. Finally, Sutton Place Investors LLC lifted its position in Pfizer by 5.6% during the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock valued at $224,000 after purchasing an additional 472 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PFE has been the subject of several analyst reports. Bank of America boosted their price objective on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Wall Street Zen raised Pfizer from a "hold" rating to a "buy" rating in a report on Saturday. Citigroup boosted their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Berenberg Bank decreased their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research note on Thursday, May 29th. Finally, Morgan Stanley boosted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Pfizer has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Stock Down 0.5%

PFE stock opened at $24.03 on Monday. The company has a market cap of $136.62 billion, a price-to-earnings ratio of 12.78, a PEG ratio of 0.78 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The firm has a 50-day moving average of $24.63 and a two-hundred day moving average of $24.20.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter last year, the firm earned $0.60 earnings per share. The business's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.2%. Pfizer's dividend payout ratio (DPR) is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.